نتایج جستجو برای: pancreatic targeting

تعداد نتایج: 231256  

Journal: :International journal of clinical and experimental pathology 2015
Li Zheng Zhongyong Zhou Zhikuan He

PFTK1 was identified as a member of the cyclin-dependent kinase (CDK) family and it is frequently upregulated in many types of tumors. However, its expression and role in pancreatic cancer has not been yet reported. In this study, we aimed to explore the expression and function in pancreatic cancer. The present study verified that PFTK1 was highly expressed in pancreatic cancer cell lines. The ...

Journal: :iranian journal of pharmaceutical research 0
kumar ganesh division of pharmaceutical sciences, sri guru ram rai institute of technology and sciences, patel nagar, dehradun. dhyani archana division of pharmaceutical sciences, sri guru ram rai institute of technology and sciences, patel nagar, dehradun. kothiyal preeti division of pharmaceutical sciences, sri guru ram rai institute of technology and sciences, patel nagar, dehradun.

the present study , was an attempt to develop galactosylated albumin nanoparticles of simvastatin for treatment of hypercholesterolemia. by developing the galactosylated nanoparticulated delivery the required action of drug at the target site at liver can be provided. the advantage of targeting helps to reduce the systemic side effects which may be occur due to the distribution of the drug to t...

Journal: :Chemical communications 2012
Demin Liu Stephanie A Kramer Rachel C Huxford-Phillips Shunzhi Wang Joseph Della Rocca Wenbin Lin

Nanoscale coordination polymers containing exceptionally high loadings of bisphosphonates were coated with single lipid bilayers to control the drug release kinetics and functionalized with a targeting ligand to endow cell-targeting capability, leading to much enhanced cytotoxicity against human lung and pancreatic cancer cells.

2011
Jameel Ahmad Khan Rachel A. Kudgus Annamaria Szabolcs Shamit Dutta Enfeng Wang Sheng Cao Geoffry L. Curran Vijay Shah Steven Curley Debabrata Mukhopadhyay J. David Robertson Resham Bhattacharya Priyabrata Mukherjee

BACKGROUND Pancreatic cancer is the fourth leading cause of cancer related deaths in America. Monoclonal antibodies are a viable treatment option for inhibiting cancer growth. Tumor specific drug delivery could be achieved utilizing these monoclonal antibodies as targeting agents. This type of designer therapeutic is evolving and with the use of gold nanoparticles it is a promising approach to ...

2013
Xiyan Wang Quentin Liu Benxin Hou Wei Zhang Min Yan Huimin Jia Haijun Li Dong Yan Feimeng Zheng Wei Ding Chao Yi Hai Wang

BACKGROUND A major challenge in the treatment of pancreatic ductal adenocarcinoma is the failure of chemotherapy, which is likely due to the presence of the cancer stem cells (CSCs). OBJECTIVE To identify side population (SP) cells and characterize s-like properties in human pancreatic cancer cell lines (h-PCCLs) and to exploit the efficacy of concomitant targeting of multiple key transcripti...

2015
Ling Wang Yanli An Chenyan Yuan Hao Zhang Chen Liang Fengan Ding Qi Gao Dongsheng Zhang

BACKGROUND Targeted delivery is a promising strategy to improve the diagnostic imaging and therapeutic effect of cancers. In this paper, novel cetuximab (C225)-conjugated, gemcitabine (GEM)-containing magnetic albumin nanospheres (C225-GEM/MANs) were fabricated and applied as a theranostic nanocarrier to conduct simultaneous targeting, magnetic resonance imaging (MRI), and double-targeted therm...

2012
Juan Iovanna Maria Cecilia Mallmann Anthony Gonçalves Olivier Turrini Jean-Charles Dagorn

Pancreatic cancer is the fourth leading cause of cancer death with a median survival of 6 months and a dismal 5-year survival rate of 3-5%. The development and progression of pancreatic cancer are caused by the activation of oncogenes, the inactivation of tumor suppressor genes, and the deregulation of many signaling pathways. Therefore, the strategies targeting these molecules as well as their...

2017
Yoshiaki Sunami Artur Rebelo Jörg Kleeff

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest cancer by 2030, and the overall 5-year survival rate is currently less than 7%. Cancer cells frequently exhibit reprogramming of their metabolic activity. It is increasingly recognized that aberrant de novo lipid synthesis and reprogrammed lipid metabolism are both associated with the development and progression...

Journal: :Advances in medical sciences 2009
P Mysliwiec M J Boucher

Pancreatic cancer is one of the most aggressive and devastating human malignancies. Despite new knowledge in the molecular profile of pancreatic cancer and its precursor lesions, survival rates have changed very little over the last 40 years. Therefore, a better understanding of the detailed mechanisms underlying the pathogenesis of this disease is critical if we expect to develop new and effec...

2018
Yong Han Yanli An Gang Jia Xihui Wang Chen He Yinan Ding Qiusha Tang

BACKGROUND Pancreatic cancer remains the leading cause of cancer-related deaths, the existence of cancer stem cells and lack of highly efficient early detection may account for the poor survival rate. Gadolinium ion-doped upconversion nanoparticles (UCNPs) provide opportunities for combining fluorescent with magnetic resonance imaging, and they can improve the diagnostic efficacy of early pancr...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید